Prime Medicine

Recent news

• Rating change
  Analysts Offer Insights on Healthcare Companies: Atricure (ATRC), Prime Medicine, Inc. (PRME) and Community Health (CYH)
  TipRanks · 2026/7/24
• Rating change
  TD Cowen Maintains Prime Medicine(PRME.US) With Buy Rating
  Market Newswire · 2026/9/25
• LifeSci Capital Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $6
  Market Newswire · 2026/10/6
• Rating change
  Oppenheimer Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $11
  Market Newswire · 2026/7/24
• Rating change
  Morgan Stanley Maintains Prime Medicine(PRME.US) With Hold Rating
  Market Newswire · 2026/8/10
• Rating change
  Chardan Capital Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $7
  Market Newswire · 2026/9/25
• Rating change
  Analysts Have Conflicting Sentiments on These Healthcare Companies: Lakefront Biotherapeutics (LKFT), Prime Medicine, Inc. (PRME) and Electrocore (ECOR)
  TipRanks · 2026/8/10
• Rating change
  Analysts Are Bullish on These Healthcare Stocks: Prime Medicine, Inc. (PRME), Edgewise Therapeutics (EWTX)
  TipRanks · 2026/9/25
• Rating change
  Analysts Are Bullish on Top Healthcare Stocks: Arcus Biosciences (RCUS), Prime Medicine, Inc. (PRME)
  TipRanks · 2026/9/25
• Rating change
  Analysts Have Conflicting Sentiments on These Healthcare Companies: Cresco Labs (OtherCRLBF), Prime Medicine, Inc. (PRME) and Steris (STE)
  TipRanks · 2026/8/7
• Rating change
  JonesTrading Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $5
  Market Newswire · 2026/8/7
• Rating change
  Chardan Capital Sticks to Their Buy Rating for Prime Medicine, Inc. (PRME)
  TipRanks · 2026/9/25
• Rating change
  Chardan Capital Reaffirms Their Buy Rating on Prime Medicine, Inc. (PRME)
  TipRanks · 2026/8/25
• H.C. Wainwright Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $8
  Market Newswire · 2026/10/1
• Rating change
  Chardan Capital Initiates Prime Medicine(PRME.US) With Buy Rating, Announces Target Price $7
  Market Newswire · 2026/8/25
• Oppenheimer Remains a Buy on Prime Medicine, Inc. (PRME)
  TipRanks · 2026/9/25
• Rating change
  Analysts Offer Insights on Healthcare Companies: Aligos Therapeutics (ALGS), ATyr Pharma (ATYR) and Prime Medicine, Inc. (PRME)
  TipRanks · 2026/8/10
• Rating change
  Analysts Offer Insights on Healthcare Companies: Prime Medicine, Inc. (PRME) and Merck & Company (MRK)
  TipRanks · 2026/9/25
• Prime Medicine, Inc. (PRME) Gets a Buy From H.C. Wainwright
  TipRanks · 2026/10/1
• Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX) and Prime Medicine, Inc. (PRME)
  TipRanks · 2026/10/6

Headlines are aggregated automatically and are not independently verified or edited by our team.